Evidence supporting the use of: Placental protein
For the health condition: Fibrosis
Synopsis
Source of validity: Scientific
Rating (out of 5): 2
Placental protein preparations have been investigated for their potential therapeutic effects in various fibrotic conditions, including liver fibrosis and skin fibrosis. The rationale for their use is based on the rich content of growth factors, cytokines, and extracellular matrix components present in placental extracts, which may modulate inflammation, promote tissue regeneration, and inhibit fibrogenesis. Several preclinical studies have demonstrated anti-fibrotic effects of placental extracts in animal models, showing reduced collagen deposition and improved tissue architecture. For example, studies have reported that placental extracts may downregulate pro-fibrotic markers such as TGF-β1 and α-SMA, and upregulate anti-fibrotic pathways. Additionally, some small clinical studies and case reports, particularly in Asia, suggest potential benefits in certain fibrotic skin conditions and wound healing. However, the overall quality of evidence is limited. Most studies are preclinical or involve small, uncontrolled human trials. There is a lack of large-scale, randomized controlled trials to establish efficacy and safety in the treatment of fibrosis. Regulatory approval for such use is not widespread, and mechanisms of action remain incompletely understood. In summary, while there is some emerging scientific basis for using placental protein in fibrosis, the evidence remains preliminary, and more robust clinical research is needed to justify its widespread therapeutic application.
Other health conditions supported by Placental protein
AnemiaBleeding (external)
Burns and Scalds
Convalescence
Fibrosis